Newsroom
latest news from ose
and across our portfolio
Featured News
All News
Portfolio NewsBarinthus BiotherapeuticsBarinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial ResultsPortfolio NewsBarinthus BiotherapeuticsBarinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November ConferencesPortfolio NewsBarinthus BiotherapeuticsBarinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate CancerPortfolio NewsBarinthus BiotherapeuticsBarinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac DiseasePortfolio NewsBarinthus BiotherapeuticsBarinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial ResultsPortfolio NewsBarinthus BiotherapeuticsBarinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus InfectionsPortfolio NewsBarinthus BiotherapeuticsVaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis BPortfolio NewsBarinthus BiotherapeuticsVaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile in Women with HPVPortfolio NewsBarinthus BiotherapeuticsVaccitech appoints industry veteran, Nadège Pelletier, Ph.D., as Chief Scientific OfficerPortfolio NewsBarinthus BiotherapeuticsVaccitech to host KOL webinar on the SNAPvax™ platform for inducing tolerance to treat celiac and other autoimmune diseasesPortfolio NewsBarinthus BiotherapeuticsVaccitech reports third quarter 2022 financial results and recent corporate developmentsPortfolio NewsBarinthus BiotherapeuticsVaccitech reports second quarter 2022 financial results and recent corporate developmentsPortfolio NewsBarinthus BiotherapeuticsVaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1Portfolio NewsBarinthus BiotherapeuticsArbutus and Vaccitech dose first patient in Phase 2a clinical trial combining therapies for the treatment of chronic hepatitis B virusPortfolio NewsBarinthus BiotherapeuticsVaccitech announces notification of milestone and royalty revenue relating to sales of VaxzevriaPortfolio NewsBarinthus BiotherapeuticsVaccitech reports full-year 2021 financial results and recent corporate developmentsPortfolio NewsBarinthus BiotherapeuticsVaccitech announces Cancer Research UK dose first patient in Phase I/IIa trial of lung cancer immunotherapy vaccinePortfolio NewsBarinthus BiotherapeuticsVaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccinesPortfolio NewsBarinthus BiotherapeuticsVaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBVPortfolio NewsBarinthus BiotherapeuticsVaccitech reports third quarter 2021 financial results and recent corporate developmentsPortfolio NewsBarinthus BiotherapeuticsVaccitech’s VTP-300 was well-tolerated and induced T cells against all targeted HBV antigens in both healthy volunteers and patients with chronic HBV infection in interim analysesPortfolio NewsBarinthus BiotherapeuticsVaccitech announces publication of second Phase 1 clinical trial results of ChAdOx1 vaccine in development for the MERS coronavirusPortfolio NewsBarinthus BiotherapeuticsArbutus Biopharma and Vaccitech announce clinical trial collaboration for chronic hepatitis B virus infectionPortfolio NewsBarinthus BiotherapeuticsVaccitech announces closing of $110.5 million initial public offeringPortfolio NewsBarinthus BiotherapeuticsVaccitech announces pricing of initial public offeringPortfolio NewsBarinthus BiotherapeuticsVaccitech appoints Joseph Scheeren, PharmD, to its Board of DirectorsPortfolio NewsBarinthus BiotherapeuticsVaccitech doses first patient in HPV001, a Phase 1/2 clinical trial of VTP-200 immunotherapeutic for high-risk persistent HPV infectionPortfolio NewsBarinthus BiotherapeuticsVaccitech completes $168 million Series B financing to advance three clinical programs through Phase 2 resultsPortfolio NewsBarinthus BiotherapeuticsVaccitech appoints two independent board directorsPortfolio NewsBarinthus BiotherapeuticsVaccitech doses first patient in HBV002, a Phase 1b/2a clinical trial of VTP-300 immunotherapeutic candidate for chronic HBV patientsOSE NewsBarinthus BiotherapeuticsBreakthrough for Oxford's covid vaccine, co-invented by VaccitechPortfolio NewsBarinthus BiotherapeuticsVaccitech expands management team with new hires, including CMO and CFOPortfolio NewsBarinthus BiotherapeuticsVaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate